PRINCETON, NJ--(Marketwire - January 04, 2011) -
| Highlighted Links |
http://www.agiletherapeutics.com |
"There is a significant unmet need in the women's healthcare product market for more convenient contraceptive options that are safe and easy for patients to use," said Al Altomari, President & CEO of Agile Therapeutics. "I'm pleased to have the opportunity to present an overview of the Phase 3 development work Agile has been doing in the company's low-dose, weekly contraceptive patch, as well as review the rest of our pipeline."
To listen to the audio webcast of the presentation during the event, please visit: http://www.agiletherapeutics.com/news_events.html. A replay of the webcast will be available an hour after the presentation for one year.
About Agile Therapeutics
Agile Therapeutics is a pharmaceutical development company specializing in women's healthcare products, with an initial focus on providing patients with more options and more convenient methods of hormonal contraception. In addition to Agile's lead, advanced-stage program to develop AG200-15, the company is developing a low-dose, progestin-only contraceptive patch, AG900. Both AG200-15 and AG900 incorporate Agile's proprietary SKINFUSION™ technology, consisting of an active and peripheral adhesive system that allows stable drug delivery and dependable adhesion over seven days. For more information, please visit http://www.agiletherapeutics.com.
